Enzymotec L (ENZY)

NASDAQ
Currency in USD
11.85
0.00(0.00%)
Closed·
Showing Enzymotec L historical data. For real-time data please try another search
Day's Range
11.8511.90
52 wk Range
0.0011.90
Key Statistics
Edit
Prev. Close
11.85
Open
11.85
Day's Range
11.85-11.9
52 wk Range
0-0
Volume
-
Average Volume (3m)
110.93K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Enzymotec L News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Enzymotec L Company Profile

Enzymotec Ltd. develops, manufactures, and markets bio-functional lipid ingredients and final products in North America, the European Union, Australia, New Zealand, Asia, and Israel. The company’s Nutrition segment develops and manufactures nutritional ingredient products based on lipids, such as phospholipids, which form the structural basis of cell membranes. Its products include Infant, a lipid ingredient for infant formula that resembles the composition and properties of human breast milk fat; Soy-PS product, a lipid ingredient used to improve cognitive and mental performance; and Krill Oil, an omega-3 bound to phospholipids. This segment also offers phosphatidylserine (PS) products, including Sharp PS, a nutritional supplement for adults to improve cognitive capabilities; and Sharp PS SILVER, a blend of PS and omega-3 to improve mental and cognitive abilities. In addition, it provides Sharp PS GOLD, a compound nutrient for improving memory in elderly persons; and Sharp PS GREEN, a soy-free PS food supplement. Further, this segment offers glycerylphosphorylcholine (GPC) products, such as Sharp GPC for improving cognitive functions for different age populations; and Sharp GPC ACTIVE, an alpha-GPC-based complex. The company’s VAYA Pharma segment discovers, develops, manufactures, and markets lipid-based medical food for the cardiovascular and neurological markets, as well as for the pharmaceutical drug markets. This segment’s products include Vayarin, a medical food for the clinical dietary management of lipid imbalances associated with attention deficit-hyperactivity disorder; Vayacog, a medical food for the clinical dietary management of lipid imbalances associated with early memory impairment; and Vayarol, a medical food for the clinical dietary management of hypertriglyceridemia. The company was founded in 1998 and is based in Migdal Haemeq, Israel. As of January 11, 2018, Enzymotec Ltd. operates as a subsidiary of Frutarom Ltd.

Earnings

Latest Release
Feb 20, 2019
EPS / Forecast
-- / 0.18
Revenue / Forecast
-- / 16.62M
EPS Revisions
Last 90 days

ENZY Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.